Wei Peng Yong
Overview
Explore the profile of Wei Peng Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
3480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, et al.
Gastric Cancer
. 2022 Jun;
25(4):741-750.
PMID: 35661944
Background: Immune checkpoint inhibitors (ICI) are now standard-of-care treatment for patients with metastatic gastric cancer (GC). To guide patient selection for ICI therapy, programmed death ligand-1 (PD-L1) biomarker expression is...
22.
Gwee Y, Chia D, So J, Ceelen W, Yong W, Tan P, et al.
J Clin Oncol
. 2022 Jun;
40(24):2830.
PMID: 35649219
The peritoneum is a common site of metastasis in advanced gastric cancer (GC). Diagnostic laparoscopy is now routinely performed as part of disease staging, leading to an earlier diagnosis of...
23.
Sgarbura O, Eveno C, Alyami M, Bakrin N, Guiral D, Ceelen W, et al.
Pleura Peritoneum
. 2022 May;
7(1):1-7.
PMID: 35602919
Objectives: Safe implementation and thorough evaluation of new treatments require prospective data monitoring and standardization of treatments. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising alternative for the treatment of...
24.
Srinivas U, Tay N, Jaynes P, Anbuselvan A, Ramachandran G, Wardyn J, et al.
Oncogene
. 2022 May;
41(24):3382.
PMID: 35523948
No abstract available.
25.
Ho J, Heong V, Yong W, Soo R, Chee C, Wong A, et al.
Ther Adv Med Oncol
. 2022 Apr;
14:17588359221087555.
PMID: 35432603
Purpose: This phase 1 study aims to evaluate the tolerability and the recommended phase 2 dose of selinexor in Asian patients with advanced or metastatic malignancies. Experimental Design: A total...
26.
Lim J, Wong A, Ow S, Ngoi N, Chan G, Ang Y, et al.
Clin Cancer Res
. 2022 Apr;
28(11):2248-2256.
PMID: 35363275
Purpose: RET is an estrogen response gene with preclinical studies demonstrating cross-talk between the RET and estrogen receptor (ER) pathways. We investigate the role of lenvatinib, a multikinase inhibitor with...
27.
Srinivas U, Tay N, Jaynes P, Anbuselvan A, Ramachandran G, Wardyn J, et al.
Oncogene
. 2022 Mar;
41(13):1986-2002.
PMID: 35236967
Inhibitors of the mitotic kinase PLK1 yield objective responses in a subset of refractory cancers. However, PLK1 overexpression in cancer does not correlate with drug sensitivity, and the clinical development...
28.
Lee M, Wong A, Ow S, Sundar R, Tan D, Soo R, et al.
Target Oncol
. 2022 Feb;
17(2):141-151.
PMID: 35195837
Background: Varlitinib is a highly potent, small-molecule, pan-HER inhibitor targeting HER1, HER2, and HER4. It has demonstrated activity in gastric, biliary tract, and breast cancers. Objective: We conducted a phase...
29.
Chakrabarti J, Koh V, Steele N, Hawkins J, Ito Y, Merchant J, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944780
(1) Background: The expression of programmed death-ligand 1 (PD-L1), which interacts with programmed cell death protein 1 (PD-1) on cytotoxic T lymphocytes (CTLs), enables tumors to escape immunosurveillance. The PD-1/PD-L1...
30.
Heiss B, Geynisman D, Martinez E, Wong A, Yong W, Szmulewitz R, et al.
Support Care Cancer
. 2021 Nov;
30(3):2803-2810.
PMID: 34845502
Purpose: Abiraterone acetate, prescribed for metastatic prostate cancer, has enhanced absorption with food. This effect was exploited in a randomized trial which showed noninferiority of PSA decline for 250 mg...